Credit Suisse Ag Aligos Therapeutics, Inc. Transaction History

Credit Suisse Ag

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$1.04 - $2.14 $14,920 - $30,702	-14,347 Reduced 99.92%	11 $0
Q1 2022 May 16, 2022	BUY	$2.08 - $12.2 $1,867 - $10,955	898 Added 6.67%	14,358 $31,000
Q4 2021 Feb 14, 2022	SELL	$11.48 - $17.69 $1,882 - $2,901	-164 Reduced 1.2%	13,460 $159,000
Q3 2021 Nov 12, 2021	BUY	$14.57 - $17.72 $198,501 - $241,417	13,624 New	13,624 $211,000

227K

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $1.3B
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.